Viatris Gives a Sneak Peek into its Upcoming Earnings

August 10, 2023

🌥️Trending News

Viatris Inc ($NASDAQ:VTRS). is giving investors a sneak peek into its upcoming earnings report. Viatris, formerly Mylan, is a leading global pharmaceutical company that focuses on producing high-quality generic and innovative medicines. The company’s upcoming earnings report will provide an overview of the company’s financial performance over the past quarter, giving investors a better understanding of the company’s financial health.

In addition, the company is also working on creating solutions for a variety of diseases affecting patients worldwide. Viatris Inc.’s upcoming earnings report will provide investors with an up-to-date look at the company’s financial performance, including its revenues and profits. Investors will also be able to get a better understanding of the company’s outlook for the near and long-term future. With its strong presence in the global pharmaceutical market, Viatris Inc. is well positioned to continue delivering strong financial results in the future.


VIATRIS INC recently released the earnings report for the fiscal year 2023 Q2 ending on June 30 2021. The report revealed that the total revenue earned by the company stood at 4577.8M USD, while it lost 279.2M USD in net income. This marks an 11.2% increase in total revenue and a 188.9% decrease in net income when compared to the previous year’s figures. Furthermore, the total revenue of VIATRIS INC decreased from 4577.8M USD to 3918.6M USD in the last three years.

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Viatris Inc. More…

    Total Revenues Net Income Net Margin
    15.6k 1.85k 12.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Viatris Inc. More…

    Operations Investing Financing
    2.5k 843.4 -3.37k
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Viatris Inc. More…

    Total Assets Total Liabilities Book Value Per Share
    48.7k 27.85k 17.38
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Viatris Inc are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    10.7% 9.0% 20.1%
    FCF Margin ROE ROA
    13.1% 9.4% 4.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Market Price

    The company opened at $10.8 and closed at $11.0, representing a 3.9% increase from the last closing price of $10.6. This rise in the stock price suggests optimism among investors ahead of the company’s upcoming earnings call. With the recent surge, Viatris Inc. looks well-positioned to continue its success in the coming weeks and months. Live Quote…


    GoodWhale has conducted an in-depth analysis of the fundamentals of VIATRIS INC to help investors better understand its financials. Our Star Chart results gave the company an overall health score of 8/10, indicating strong cashflows and debt that can support its operations and allow it to pay off its debts. We have also classified VIATRIS INC as a ‘rhino’, a type of company which has achieved moderate revenue or earnings growth. When looking at the company’s performance across different metrics, it is clear that it is strongest in liquidity, medium in dividend, growth, and profitability, and weakest in asset. This means that VIATRIS INC may be well suited for investors who prioritize access to cash and income more than growth or long-term potential. Investors who are looking for a stable income from a reliable source could find VIATRIS INC to be an attractive option. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company has a rich history of more than 150 years, dating back to the founding of its predecessor companies, which include some of the world’s most well-known brands. Today, Viatris is a leading provider of essential medicines and solutions, with a presence in more than 150 countries and a workforce of over 30,000 people. The company’s mission is to provide access to high-quality medicines and solutions for patients and customers around the world. Viatris is committed to being a trusted partner for patients, customers, employees, shareholders, and society. The company’s products are available in a wide range of therapeutic areas, including cardiovascular, diabetes, oncology, respiratory, and other conditions. Viatris has a portfolio of more than 1,000 products, including many that are essential medicines. The company also offers a range of services, including manufacturing, distribution, and logistics, to support its customers and patients. Viatris’s competitors include Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, and other global pharmaceutical companies.

    – Pfizer Inc ($NYSE:PFE)

    Pfizer Inc is an American multinational pharmaceutical corporation. It is one of the world’s largest pharmaceutical companies. The company was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York. The company’s headquarters are in New York City. The company’s products include medicines and vaccines for a wide range of medical conditions and diseases.

    – Teva Pharmaceutical Industries Ltd ($NYSE:TEVA)

    Teva Pharmaceutical Industries Ltd is a pharmaceutical company with a market cap of 9.07B as of 2022 and a Return on Equity of -9.35%. The company focuses on producing generic drugs and active pharmaceutical ingredients. Teva is the world’s largest manufacturer of generic drugs and one of the world’s largest pharmaceutical companies.

    – GSK PLC ($LSE:GSK)

    GlaxoSmithKline PLC is a British pharmaceutical company with a market capitalization of 58.8 billion pounds as of 2022. The company has a return on equity of 34.04%. GlaxoSmithKline is a global healthcare company that researches, develops, and manufactures pharmaceuticals, vaccines, and consumer healthcare products.


    Viatris Inc. is a healthcare company that provides drugs and other health-related items to customers around the world. Investing in Viatris Inc. can be a great opportunity for investors because of the company’s recent success. In the last quarter, Viatris Inc. reported a significant increase in revenue and profits, and their stock price moved up accordingly. Analyzing the company’s fundamentals, analysts have noted that their financials are strong and that their industry has good prospects for growth.

    Furthermore, investors have noted that the dividend yield is attractive relative to other stocks in the same sector. With a well-diversified portfolio, Viatris Inc. may be an attractive opportunity for investors looking to benefit from the company’s long-term growth potential.

    Recent Posts

    Leave a Comment